Published: Apr 2016
ACE Report #8928
Ace Report Cover Metabolic Disorders

WCO-IOF 2016: Daily subcutaneous abaloparatide vs teriparatide & placebo for osteoporosis

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Effects of abaloparatide on vertebral, nonvertebral, major osteoporotic and clinical fracture incidence in postmenopausal women with osteoporosis: result of the phase 3 ACTIVE trial

Contributing Authors: LA Fitzpatrick P Miller F Cosman D Black E Lau CAF Zerbini BJ Riis C Christiansen G Williams MY Hu G Hattersley

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.